87: The spelling of immortality in the Soyinka canon, By Uzor Maxim Uzoatu – Premium Times

It beggars belief that Soyinka has made it to the heavy age of 87 after a life of multiform dangers: an unknown gunman invading the broadcasting house to replace the premiers tape, going to Biafra in a season of anomie, enduring imprisonment and solitary confinement, bearing the wounds of exile, daring Abacha etc. In short, way beyond the claims of the evangelical churches, the only miracle I see is Wole Soyinkas life.

He was so daring early in life that nobody gave him any chance of living up to 87 years on this earth. But here we are: Professor Oluwole Akinwande Soyinka, that is Wole Soyinka for short, is 87 today.

On my small part, I did not want anything to do with schooling anymore, being much of a tearaway in my youth then I saw the name of Professor Wole Soyinka as the Head of the newly created Dramatic Arts Department at the then University of Ife.

My plans had been to head into the bush to change the system as a guerrilla fighter, but once I learnt of the Soyinka school at Great Ife, I applied and was taken.

Aside from his genius in literature, Soyinka ranks amongst the greatest freedom fighters ever, a foremost defender of the sanctity of the human life.

The first African to win the coveted Nobel Prize for Literature in 1986, he is an accomplished playwright, poet, novelist, memoirist, filmmaker, director, translator, actor, director, singer, activist, humanist, aesthete, connoisseur, and above all else, a human being, and a very remarkable oneat that.

Wole Soyinka threw a party for my class on graduation, declaring us the most challenging students he had ever taught. Of course everybody knows that praise from Soyinka does not come easily. His word is his sword!

This does not at any rate qualify me as an exemplary student. Back then at the University of Ife, I was with my Dramatic Arts classmates in Soyinkas house for practical lessons on television production based on Edith Uche Enems play. I did not care a kobo about the lesson. I told Soyinkas steward, the Ghanaian lad Francis, to get me a cool Star lager beer from the refrigerator. I was nursing my beer gloriously while Soyinka taught my classmates. Then he saw me drinking the beer. He didnt get mad at me. He asked why I was drinking beer while my fellow students were learning and I promptly told him: Prof, sir, thats how I get my inspiration. Soyinka just cast a fatherly benign look at me in the manner of some fathers do have them and continued with his teaching.

After my degree exams, I was totally out of cash. I needed money badly, and I ran to Soyinka in his office. I told him I had no money to go home. He gave me all the money he had. In a show of bravado I told him I would pay him back his money when I came for convocation. Soyinka had a healthy laugh and said: How am I sure you will not run through the money and come back with another sob story?

Soyinka took us on a course in Humanism. It was class war all the way because most of us in the class were Marxists. We asked Soyinka to join us in the bush of guerrilla struggle, instead of being an arm-chair humanist! He was never angry with our youthful ebullition, only advising us that we would get to understand society further as we grew in life.

The truth, of course, is that I only went to Ife because Soyinka was there. I did not care for university education. I went to Ife in 1978, with Soyinka as my Head of Department. Then there was Okot pBitek, the inimitable Ugandan poet of theSong of Lawino fame, in the literature department. Soyinka was always travelling all over the world, while Okot was an ever-present company. Soyinkas Ghanaian boy, Francis, was, of course, around to attend to my needs in Soyinkas gods-festooned home. Soyinkas sister, Folabo Ajayi, was also around, always wondering at my age on account of my multiform high jinks, whilst we were rehearsing Akinwunmi Isolas play Madam Tinubu, directed by Femi Euba, which we took on tour to Ibadan and Lagos.

Our first experience of Soyinka as a teacher was, yes, very dramatic. He was to teach us Shakespeares King Lear. We had all come from secondary schools where Shakespeare was read line-by-line and explained by the class teacher. In Soyinkas case, we were all seated in the Pit Theatre at Ife when he casually strolled in. He distributed sheets of cyclostyled paper in which a speech taken out of King Lear was printed. Soyinka asked us to pick out the unnatural word in the speech. None of us could understand this kind of teaching. He then said we ought to have still been in high school. The West Indian lady, Dr Carroll Dawes, had to come to our rescue by teaching us King Lear, line after line, at Oduduwa Hall for weeks and months on end.

In the course of our Ife studies, we had to read up all the plays of Bertolt Brecht as our special author. We found to our chagrin that Brecht was a rival of Shakespeare in the large number of plays written. My classmates and I had to confront Soyinka with the charge that he was making us read for a Ph.D when we only applied to earn a bachelors degree! Soyinka asked us to arrest Dr Yemi Ogunbiyi as the culprit who gave us more books to read than doctoral candidates.

Soyinka took us on a course in Humanism. It was class war all the way because most of us in the class were Marxists. We asked Soyinka to join us in the bush of guerrilla struggle, instead of being an arm-chair humanist! He was never angry with our youthful ebullition, only advising us that we would get to understand society further as we grew in life. Interestingly, the very next year, Soyinka asked a Polish lady who barely spoke English to take us in the course of Aesthetics in his place! We were thus denied of the opportunity to argue with the lady as we argued with Soyinka.

His intervention on road safety happened before our very eyes whilst at Ife. He had no stomach whatsoever for dangerous driving that killed many along the notorious Ife-Ibadan road. He would bring his friend, Femi Johnsons jeeps into the campus and we were even quite used to Bola Iges vehicles as the then governor of Oyo State. For Soyinka, a vehicle was just a vehicle.

After leaving school, I tried my hands at peasant theatre. I sent the play I wrote, A Play of Ghosts, to Soyinka and it was only much later that I got to know that he forwarded the play to the American director, Chuck Mike, for production. Soyinka does all these favours without asking for any attention whatsoever.

When I ran into Soyinka at poet Odia Ofeimuns birthday party, he wondered aloud where I had been all these years. I replied him that I had all along been in Nigeria doing a great battle with Nigerian poverty. At the time his memoirs You Must Set Forth At Dawn was just published, and I learnt from the novelist, Okey Ndibe, that Soyinka was to do a reading for an organisation run by white ladies in the heart of Victoria Island, Lagos. When Okey and I got to the venue, Soyinka asked me to select the passage that he would read. I told him I did not have a copy of the book ready at hand. He then off-handedly told me that his publisher, Bankole Olayebi, was my friend, in which case I would not have much trouble getting a free copy!

Of course, I am very proud of my teacher, the very first black man to win the coveted Nobel Prize in Literature in 1986. Back in time, my crystal ball did not hide anything when it revealed to me that Soyinka would win the Nobel, a first for Africa, in the year 1985. I told not a few friends that the Nobel was definitely coming that year, and it was such a shocker when the prize went instead to the obscure French novelist, Claude Simon. Well, it is remarkable that Claude Simons first novel bears the very unfunny title, The Cheat.

Soyinka is at heart a jovial soul. From teaching the art of wine to a young Italian girl, to setting a trap for wine-thieves in his then Ife home, Soyinka is the master of his universe. Humour is never lacking in his forte. For instance, an Igbo classmate of mine with a thick Igbo accent asked Soyinka a question in class, only for Soyinka to reply: Are you an Ibadan man?

There was no denying Soyinka the very next year, 1986, when the Nobel Prize for Literature landed on our shores. Soyinka had just made the flight from Cornell University, New York, where he was then teaching, to the International Theatre Institute (ITI) in Paris to attend the executive meeting of the world body, which he headed. His plan was to spend some quiet time at the apartment of his cousin, Yemi Lijadu. He found his cousin giddy with joy: The news just broke that Nigerian playwright Wole Soyinka had won the 1986 Nobel Prize for Literature, thus becoming the first African to win the coveted award.

For reasons no one can really explain, the name Kongi has stuck with Soyinka amongst his students and colleagues, even though the character in question in the eponymous play is highly detestable. Behind Soyinkas back, some of us call him Langage, pronounced as Longage, taken from his Inaugural Lecture at Ife entitled The Critic And Society: Barthes, Leftocracy And Other Mythologies.

Soyinkas collection of poetry, Samarkand and Other Markets I have Known, was launched in 2002 at the National Theatre under a tree that is now known as the Samarkand Tree. Soyinka autographed my copy of the book right under that famous tree. The long poem Elegy for a Nation dedicated to Chinua Achebe at Seventy is quite striking. Soyinka had wanted to read the poem at An Evening With WS sponsored by Globacom, but there was too much noise at the Golden Gate, Ikoyi venue, such that it did not provide the right mood for the Nobel Laureate to pay homage to his great compatriot. It was at that event that I asked Soyinka the question: Why are you not a born-again Christian? He duly replied thusly: I have my own religion; thank you! It is a matter of great joy that Soyinka still continues in the onerous task of supporting younger writers, like the irrepressible Onyeka Nwelue. I treasure on my bookshelf a hardback copy of The Second Genesis: An Anthology Of Contemporary World Poetry which features some of my poems, alongside those of my teacher, Soyinka, and my dear compatriots, Ikeogu Oke and Obari Gomba. The book which features poets of 60 countries, from Albania to the United States, is indeed a heavy feast of comparative humanity, a cause to which Soyinka has dedicated his venerated life.

Soyinka is at heart a jovial soul. From teaching the art of wine to a young Italian girl, to setting a trap for wine-thieves in his then Ife home, Soyinka is the master of his universe. Humour is never lacking in his forte. For instance, an Igbo classmate of mine with a thick Igbo accent asked Soyinka a question in class, only for Soyinka to reply: Are you an Ibadan man?

At Freedom Park, Lagos, during the 60th birthday celebration of Kunle Ajibade, the journalist jailed for life by General Sani Abacha, Soyinkas kind and personable wife, Folake Wole-Soyinka, provided two thousand naira for the Nobel Laureate to give to Adunni and her Nefertiti dancers, only for WS to sharply nick one thousand naira into his own pocket and give the musicians the remaining one thousand naira!

Wole Soyinka is still as fecund as ever. I was so happy to break the world exclusive news of Soyinka publishing his third novel, Chronicles from the Land of the Happiest People on Earth, just after the wave of the COVID-19 onslaught. The great man is still hard at work, writing more immortal books.

It beggars belief that Soyinka has made it to the heavy age of 87 after a life of multiform dangers: an unknown gunman invading the broadcasting house to replace the premiers tape, going to Biafra in a season of anomie, enduring imprisonment and solitary confinement, bearing the wounds of exile, daring Abacha etc. In short, way beyond the claims of the evangelical churches, the only miracle I see is Wole Soyinkas life.

Uzor Maxim Uzoatu is a student of the Nobel Laureate.

Donate

TEXT AD: To advertise here . Call Willie +2347088095401...

See original here:
87: The spelling of immortality in the Soyinka canon, By Uzor Maxim Uzoatu - Premium Times

The history of Boromirs Walk to Mordor meme is Lord of the Rings magic – Polygon

In Peter Jacksons The Fellowship of the Ring, Elrond calls a secret meeting with representatives of the three free races in Middle-earth humans, elves, and dwarves to discuss what to do about the One Ring. As Elrond commands that the ring must be destroyed in the fires of Mount Doom, Boromir utters a line that has since become one of the most iconic Lord of the Rings memes of all time: One does not simply walk into Mordor.

Sean Bean, who plays Boromir, delivers the line with the gravitas necessary for the movies pivotal scene. However, the contrast between his serious line reading and the fact that the quote comes after a brief pause and almost out of nowhere caught the attention of Lord of the Rings fans. A screencap of the scene, featuring Boromir making a circular hand gesture, overlaid with the famous line quickly became a popular meme, spreading across major social sites of the time.

When the first film was released in 2001, memes were just beginning to find their footing online. They had been around for years one of the first modern memes, a dancing CGI baby, became popular in 1996 but the landscape was rapidly evolving. At the same time, fandoms were thriving on websites and forums meant to connect members around the world.

Lord of the Rings memes arrived in the digital space at a moment where dedicated fanbases were purposely trying to share as much content with as many people as possible. The fun of making memes attracted people who hadnt seen the movies, who watched the movies so they could make better memes, which attracted more people and ... the rest is history, a symbiotic relationship that has kept the Peter Jackson trilogy front and center in online consciousness for two decades.

From owyns iconic I am no man scene in The Return of the King, to a line about menus, uttered by an Uruk-hai in Two Towers, which has captivated and confused the internet for years, there are dozens upon dozens to choose from. An online search of Lord of the Rings memes produces hundreds of articles chronicling the best and most known. Pages have popped up on almost every social media site to allow fans to share their love of the memes, from Reddits r/LOTRmemes to Instagrams @danklotrmemes and Tumblrs LOTRreactionmemes.

Boromirs Mordor meme isnt the only Lord of the Rings meme in rotation, but Walking to Mordor is one of the oldest and most recognizable from the franchise. While the image became part of the internets meme lexicon after the movies release in 2001, one of the first noted uses wasnt until 2004, when a user on the forum Something Awful posted an image of Boromir in a car with the text One does not simply drive into Mordor.

The original moment from the film was itself popular, but this adaptation of the line rocketed it to another level. The edited version of the meme situated it as a snowclone, a formulaic phrase that can be customized but still convey the same origin. Other iterations, like One does not simply insert a USB on the first try and One does not simply hit the snooze button just once, began popping up across the internet, cementing the memes status in the digital space. It was a straight-forward template that could be adapted to any phrase, making it an easy format for seasoned and new meme users alike to enjoy. Ultimately, it helped pave the way for similar snowclone memes to thrive.

Its just an easily digestible, low-effort meme from a simpler time, Redditor and member of r/LOTRmemes u/bottle_O_pee says. That being said, that meme became so popular [that] it started a sort of renaissance in the meme world.

Now, though, the memes purpose has drastically changed. The humor behind it has evolved from being a funny, culturally-relevant twist on the meme to an indicator of someone doing something inane or ridiculous. While its widespread use was a major factor of this change, it also became common knowledge that the line in the meme isnt actually what Boromir says at that moment in the film hes actually talking about the great Eye of Sauron, hence his curled hand contributing to its absurdity. Meme humor has also majorly evolved, favoring smarter topics or formats and directly contrasting with the memes uncreative, template-like layout. To use the Boromir meme nowadays is to understand that it has been run into the ground, but that its too integral to internet culture to ever really die.

Lord of the Rings memes are popular because the series is popular, says u/bottle_O_pee. Sometimes [the] simplest answer is the best.

While the breadth of memes that the franchise has spawned is impressive, whats more is how long the memes have stuck around. Boromirs line, for example, has been passed around the internet for 20 years, long surpassing the typical four-month life span of a meme.

In many ways, the longevity of the trilogys memes is a reflection of its fandom. Lord of the Rings fans have been around since the first books publication in 1954; Fanlore even published a 100-year timeline of the fandom. What solidified the fanbase as a major cultural group, though, was its passionate dedication to the franchise and to Tolkien himself. Fans have created clubs around it, lined up for hours to see the films, and just like the Year of the Ring project is doing, dissected every single aspect of the source content through articles, podcasts, and documentaries.

That commitment to the trilogy is as strong today as its ever been, thanks to the stories launch into the mainstream by the films and the internets ability to deliver Lord of the Rings content to almost anyone anywhere at any time. The Reddit page r/LOTR has seen its subscriber count increase by over 4600% since just 2013, and an unfathomably detailed wiki continues to chronicle every corner of the trilogy and its fans and these are just a small sampling of the fandoms growth and dedication.

It doesnt matter that it came out 20 years ago, says Cates Holderness, head of editorial and trends expert at Tumblr. [Fans are] rewatching it every couple of weeks, and they have found a community of people who also love these movies. They can engage forever with this one entertainment property.

This increase can also be attributed to circulation of Lord of the Rings memes online. As they spread across the internet, anyone who interacts with the memes also engages with the films, regardless of how far removed from the content they are. For non-fans, theyre a gateway into a fantasy world that otherwise requires an immense amount of time to get into. Memes allow a person to dip their toes into the Lord of the Rings, without putting in the considerable effort to unpack its story. Its a constant cycle; as new fans are introduced to the story through memes, they become meme creators and circulators themselves, pulling in more new fans as they go.

The Lord of the Rings films have also managed to become a cultural keystone in their two-decade-long existence. Even those who havent seen or read the trilogy have heard of it, typically knowing at least some general plot points. The major characters themselves have become entities separate from the story. Referring to Gandolf or Frodo nowadays doesnt always pertain to the Lord of the Rings books or movies; to many, the former is just a funny, slightly neurotic wizard, and the latter is a small, furry-footed hero, both fully removed from their original context.

Because there is now such a widespread cultural understanding of the trilogy, Lord of the Rings memes can be used and comprehended by everyone not just fans. One does not simply walk into Mordor is funny because fantasy heroes can never just waltz into the climax of the story; its a universal story element, rather than one tied to a specific world. Neither the character of Boromir nor the line he utters are important to the meme at all; instead, its the cultural perception that propelled it to the top of the meme charts and has kept it there ever since.

Theres a low barrier of entry when it comes to memes, because so much of the language and the cultural understanding of memes is ubiquitous, says Holderness. The context is there without having to have seen the movies.

The films themselves are also infinitely quotable, from Samwise Gamgee proclaiming Theres some good in this world, Mr. Frodo, and its worth fighting for in The Two Towers, to a visibly sober Legolas saying I think its affecting me after a drinking competition with Gimli in The Return of the King. Because of the number of memorable lines that Jackson and co-writers packed into the script, almost every scene has at least one moment that could easily be transformed into a meme.

In general, the movies are long, and there are several of them, [] so we have that much material, says Holderness. Its just a lot of fodder for memes. Its fun, its interesting, the characters are complex but also funny at the same time. I think that kind of all builds out a great base for people to just riff on and make things out of.

That ability to explore such a large amount of content means that Lord of the Rings memes can feasibly cater to everyone. You dont have to look far for a meme that fits what youre trying to convey from the joys of drinking with friends to the aftermath of cleaning a messy room to simply a funny joke based on a specific scene. Not only does the vast material allow for constant meme creation, but it also encourages continuous circulation; you can always find at least one Lord of the Rings meme out there to relate to or that you find funny.

One does not simply use a Lord of the Rings meme casually theres a rich story behind every image and line, and at least part of it has to be understood in order for the joke to make sense. These memes level the playing field, though; those who only vaguely know the stories because of cultural importance can enjoy the memes just as much as those who harbor a deep passion for the story behind them.

In the same way that the series is so profoundly embedded in our culture, the memes that come from it have garnered their own kind of fame. At this point, for example, the Boromir meme is a living legend. It was created in a time of image macros memes that consist of an image with top and bottom text in the Impact font and it survived the transition into what we consider memes today.

Thanks to dedicated digital fans and a constant adaptability in the changing internet landscape, Lord of the Rings memes have been circulating for 20 years, squarely situating themselves as a major part of internet culture. These memes have so much to be enjoyed, and to be, and to do, and like Samwise Gamgee their part in the story of The Lord of the Rings will certainly go on.

The rest is here:
The history of Boromirs Walk to Mordor meme is Lord of the Rings magic - Polygon

The Immortal Trailer and Poster Revealed by HBO Max – VitalThrills.com

HBO Max has released the official trailer and poster for The Immortal (LImmortale), the feature film spin-off from the acclaimed Max Original series Gomorrah debuting July 29.

The movie finds the notorious, indestructible Naples mobster Ciro Di Marzio (Marco DAmore) in Riga, Latvia, where he turns a low-level counterfeit goods syndicate into a major drug trafficking enterprise despite the incalculable risks.

After reuniting with his first mentor Bruno (Salvatore DOnofrio) and receiving his latest mission, an exiled Ciro is left to fearlessly confront whatever comes his way, navigating a new chapter of gang warfare while grappling with devastating memories of loss and trauma.

Weaving between Ciros past as an orphan in Naples cruel underworld and his present as a hardened, cunning assassin with nothing left to lose, The Immortal plunges into the cold, dark depths of a world where immortality is just another form of damnation.

Based on the book Gomorra by Roberto Savino, the film is directed by Marco DAmore from a screenplay by Leonardo Fasoli, Maddalena Ravagli, Marco DAmore, Francesco Ghiaccio, and Giulia Forgione.

From a story by Leonardo Fasoli, Maddalena Ravagli, Marco DAmore, and Francesco Ghiaccio, the film is produced by Riccardo Tozzi, Giovanni Stabilini, Marco Chimenz, and Gina Gardini.

HBO Max released the fourth season of Gomorrah on May 20th. The critically-acclaimed third season debuted exclusively on HBO Max this January.

The new season turns the spotlight on Genny (Salvatore Esposito), the lone Savastano dynasty survivor: a character who has shed countless skins in the process of morphing from Don Pietros spoiled brat into family boss, husband and father.

The new season sees him on his best behavior precisely for the sake of Azzurra (Ivana Lotito) and little Pietro: with his own family to protect and an activity to reboot, he feels the need for a major life change, committing to legit business while sneaking out, as best he can, from the world his father had him grow up in.

His interests in Naples are now entrusted to Patrizia (Cristiana DellAnna) who, having first betrayed and then killed Scianel, former female leader of The Alliance, has earned her rank within the Savastano clan. Along with Genny, to level the scores and keep the peace in gangland, they will lean on the Levante clan, a branch of late Donna Immas family.

Meanwhile Enzo (Arturo Muselli) and Valerio (Loris De Luna), having tightened their grip over the central Naples turf, are faced with new challenges.

Based on an idea by Roberto Saviano, the fourth season of Gomorrah was produced by Cattleya part of ITV Studios Sky, Fandango in collaboration with Beta Film.

The series is executive produced by Cattleyas Riccardo Tozzi, Gina Gardini, Giovanni Stabilini and Marco Chimenz as well as by Nils Hartman and Sonia Rovai for Sky and developed by Stefano Bises, Leonardo Fasoli, Maddalena Ravagli and Roberto Saviano.

The teleplays were written by Leonardo Fasoli, Maddalena Ravagli, Enrico Audenino and Monica Zapelli. The fourth season was directed by Francesca Comencini who is also the artistic supervisor Claudio Cupellini, Marco DAmore, Enrico Rosati and Ciro Visco.

View original post here:
The Immortal Trailer and Poster Revealed by HBO Max - VitalThrills.com

YouTube Gold: Its Hard To Think Of Anyone Who Ever Showed More Heart In A Basketball Game Than This – Duke Basketball Report

Every so often, the NBA playoffs bring iconic moments. Consider the magnificent block Giannis Antetokounmpo had against DeAndre Ayton in Game 4 of this years Finals. Or the rundown block LeBron James had against the Warriors in 2016 (and notice that the block was kept in bounds and that Cleveland got the possession - very smart play). Or take this play by Michael Jordan against the Cavaliers in his era when nobody was going to get by the Bulls.

However, there is one iconic moment that took place even before the ball went up to start the game.

Were referring to the 1970 Finals between the Lakers and the Knicks. Willis Reed entered Game 7 with a torn thigh muscle and was not expected to play. He was determined though and took treatment - probably cortisone - and hobbled out shortly before the game started.

His assignment was Wilt Chamberlain, the most supremely talented big man in the history of sports. Not just basketball. Sports. You can take any athlete over 6-8 and Chamberlain could have mastered that sport and won. Thats how spectacular his talent was.

Thats what Reed had to deal with - on one leg.

Nonetheless, he had the crowd in a frenzy and after he hit the first two shots of the game, the energy in Madison Square Garden was off the charts. There was no way LA could match it.

Afterwards, Howard Cosell told Reed that [y]ou exemplify the very best that the human spirit can offer.

This is one of the legendary moments in all of sports.

Read the rest here:
YouTube Gold: Its Hard To Think Of Anyone Who Ever Showed More Heart In A Basketball Game Than This - Duke Basketball Report

50 Cent Confirms He Has Scrapped The Original ‘Street King Immortal’ Album | HipHop-N-More – HipHop-N-More

50 Cents much awaited new show Raising Kanan, a part of the POWER spinoff series, debuts on Sunday, July 18.

The G-Unit mogul is confident that the show will be even bigger than the original Power which ended up being one of the highest rated shows on the Starz network. Up next is the Black Mafia Family series on Starz, and along with it will come new music from the rapper in form of a soundtrack.

However, in a new interview with The Independent, 50 was asked about his long delayed Street King Immortal album which he originally started promoting back in 2012. Even until a couple of years ago, there was hope that the album might see the light of day as back in 2018, he had mentioned that it was coming at the end of that year.

But it looks like 50 has finally decided to scrap the album. When the topic came up, Curtis says the original version of that album will not be released but to make up for it, he will drop new music in September. That is most likely in reference to the soundtrack hes putting together for BMF.

That original version is not [being released], but Im releasing new music in September, he said. He also added that Eminem will not feature on the project as he didnt get to finish the songs he recorded with him for the SKI album (remember Champions ?) I didnt finish the tracks with him Im not gonna tell whos on it because Im the most exciting person [on the album].

Lets hope we get at least a few 50 Cent songs on the upcoming soundtrack. Last week, it was also announced that 50 will also be producing a Hip-Hop competition show Unrapped at ABC.

Read the rest here:
50 Cent Confirms He Has Scrapped The Original 'Street King Immortal' Album | HipHop-N-More - HipHop-N-More

What is the Olympic Hymn, the choral cantata composed for the first-ever Summer Olympics in 1896? – Classic FM

19 July 2021, 13:39 | Updated: 19 July 2021, 14:31

The official anthem of the Olympics is heard when the Olympic flag is raised and lowered at the opening and closing ceremonies.

This is the story of the stirring choral anthem that marked the first-ever modern Olympic Games in 1896 and will mark the Games as they return in 2021.

The Olympic Hymn is a choral cantata composed by Greek opera composer Spyridon Samaras, with lyrics by the Greek poet Kostis Palamas.

It was written for the first summer Olympic Games in modern history, which took place in Athens and saw fourteen nations, and over 200 athletes, compete in the Greek capital.

It was Demetrius Vikelas, the first president of the International Olympic Committee (IOC), who chose both artists to pen this important work. The hymn was first heard during the Opening Ceremony of the first instalment of the games, which was formally called the Games of the I Olympiad.

Read more: The best classical music written for the Olympic Games

For the following Olympics, nations took on the tradition of commissioning their own anthems for ceremonies, until 1956 when the hymn was used again. In 1958, the IOC declared Samaras Olympic Hymn the official anthem of the games, and it was sung, in its English version, at the 1960 Winter Olympics in Squaw Valley in the US.

The Olympic Hymn from then on had an important place in the meticulously laid-out opening and closing ceremonies of the Olympics, the rigorous orders of which have been determined and entrenched by the IOC. Since being declared the official anthem, the hymn has been heard at every Olympic games during the Opening Ceremony as the Olympic Flag is raised, and during the Closing Ceremony when the flag is lowered.

The IOC decreed that the Olympic Hymn should be performed in Greek or English, or else in the host nations language as long as it was translated from the original Greek of Palamas pen.

Read more: Mr Bean joins London Symphony Orchestra for genius musical Olympics sketch

The piece itself is an optimistic, brass fanfare-fronted choral cantata in a major key. It has an invigorating melody that embodies strength and hope.

The songs words are also drenched in unfailingly uplifting messages of hope, bravery and victory, telling of the immortal Olympic Flame and how it can unite, inspire and bring honour as it lights the way for nations and our sporting heroes, as they come together every (mostly) four years.

With that, lets take a look at the rousing lyrics.

Olympian flame immortalWhose beacon lights our wayEmblaze our hearts with the fires of hopeOn this momentous day

As now we come across the worldTo share these Games of oldLet all the flags of every landIn brotherhood unfold

Sing out each nation, voices strongRise up in harmonyAll hail our brave OlympiansWith strains of victory

Olympic light burn on and onOer seas and mountains and plainsUnite, inspire, bring honour

To these ascending gamesMay valour reign victoriousAlong the path of golden way

As tomorrow's new champions now come forthRising to the fervent spirit of the gameLet splendour pervade each noble deedCrowned with glory and fame

And let fraternity and fellowshipSurround the soul of every nation

Oh flame, eternal in your firmament so brightIlluminate us with your everlasting lightThat grace and beauty and magnificence

Shine like the sunBlazing aboveBestow on us your honour, truth and love

Read more from the original source:
What is the Olympic Hymn, the choral cantata composed for the first-ever Summer Olympics in 1896? - Classic FM

TenZ explains why theres no real difference between top ranks in Valorant – Dexerto

Sentinels star Tyson TenZ Ngo has explained that he believes grinding to be the only defining factor between Diamond, Immortal, and Radiant players in Valorant.

While there are many factors outside of a players control, like being stuck alongside a four-stack of untalkative teammates or a Jett who refuses to entry, theres plenty of aspects that are in a players control when climbing Valorants ranked ladder.

The most obvious way to contribute is through having a pure mechanical ability to get kills. The difference in players ability to frag is much more obvious at lower levels, but, at elite ranks, players shooting ability is largely similar.

And TenZ who famously became the NA servers first player to reach the top rank of Radiant (or Valorant, as it was confusingly called back in beta) has explained that the ability to grind is the only real deciding factor between the top ranks.

On his July 16 Twitch stream, TenZ said that he believes theres not much difference between players in Diamond, Immortal, and Radiant.

There is no deciding factor for what makes an immortal player more distinguishable than a Radiant player, he said. It really is just who grinds more.

And at the end of the day, even Radiant and Diamonds to an extent are kind of the same sh*t.

TenZ had earlier spoken about a mental block that Diamond players can face when against Radiants, caused by intimidation over their opponents being a higher ELO.

Dont think about it. Dont let their ranks be scary, he advised.

Given how he took to Sentinels roster like a duck to water in turbulent circumstances its no surprise TenZ has such a winning mentality. Itll serve him well heading into the remainder of VCT Stage 3 as Sentinels continue their domination of NA (and potentially the world).

See original here:
TenZ explains why theres no real difference between top ranks in Valorant - Dexerto

Advances in the Genetic Etiology of Hearing Impairment – PRNewswire

WASHINGTON, July 19, 2021 /PRNewswire/ --A recently published article in Experimental Biology and Medicine (Volume 246 Issue 13, July, 2021)describes a new genetic mutation linked to hearing impairment. The study, led by Dr. Ambroise Wonkam in the Division of Human Genetics, Faculty of Health Sciences at the University of Cape Town (South Africa), reports a variant of the DMXL2 gene in Cameroonian families with hearing impairment.

The inability to hear properly in one or both ears impacts nearly 6% of the global population. Hearing impairment can be caused by environmental or genetic factors. However, establishing a definitive genetic cause can prove difficult in some cases. Approximately 70% of genetic related hearing impairment cases are non-syndromic and occur without the presence of other clinical factors. Over 120 genes have been linked to non-syndromic hearing impairment.While most cases in Europe and Asia can be traced to variants in a single gene, the GJB2 gene, the etiology of African non-syndromic hearing impairment cases is unresolved.

In this study, Dr. Wonkam and colleagues used direct sequencing methods to analyze DNA samples from a Cameroonian family with non-syndromic hearing impairment (NSHI). A mono-allelic missense variant [NM_015263.5:c.918G>T; p.(Q306H)] was identified in the DMXL2 gene in this family.This variant was present in the heterozygous state in the affected mother and the two affected children (one male and one female), and absent from the other two unaffected children (one male and one female). The variant was absent from many genome databases, over 120 control individuals from Cameroon, and 112 isolated cases of NSHI from Cameroon. This is the first report implicating DMXL2 in NSHI in Africans and confirms a previous report of this variant in China.Dr. Wonkam said, "DMXL2 is now a confirmed NSHI candidate gene in Cameroon, and more studies are needed to assess its implication in other populations around the world."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said "Dr. Wonkam and colleagues have identified a mono-allelic variant in DMLX2, also called rabconnectin-3a (RC3), in a Cameroonian family with hearing impairment. A similar variant was previously found in a Han Chinese family. It is very interesting that RC3 is found on inner ear hair cells and is a part of a synaptic vesicle protein complex involved in Ca2+-dependent neurotransmitter release in brain. Future studies aimed at a detailed understanding of the role of DMXL2 in hearing impairment is warranted."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit http://www.sebm.org. If you are interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

image1.png

SOURCE Experimental Biology and Medicine

View original post here:
Advances in the Genetic Etiology of Hearing Impairment - PRNewswire

funded study finds gene therapy may restore missing enzyme in rare disease – National Institutes of Health

Media Advisory

Friday, July 16, 2021

Results provide hope for children with aromatic L-amino acid decarboxylase deficiency.

A new study published in Nature Communications suggests that gene therapy delivered into the brain may be safe and effective in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare neurological disorder that develops in infancy and leads to near absent levels of certain brain chemicals, serotonin and dopamine, that are critical for movement, behavior, and sleep. Children with the disorder have severe developmental, mood dysfunction including irritability, and motor disabilities including problems with talking and walking as well as sleep disturbances. Worldwide there have been approximately 135 cases of this disease reported.

In the study, led by Krystof Bankiewicz, M.D., Ph.D., professor of neurological surgery at Ohio State College of Medicine in Columbus, and his colleagues, seven children received infusions of the DDC gene that was packaged in an adenovirus for delivery into brain cells. The DDC gene is incorporated into the cells DNA and provides instructions for the cell to make AADC, the enzyme that is necessary to produce serotonin and dopamine. The research team used magnetic resonance imaging to guide the accurate placement of the gene therapy into two specific areas of the midbrain.

Positron emission tomography (PET) scans performed three and 24 months after the surgery revealed that the gene therapy led to the production of dopamine in the deep brain structures involved in motor control. In addition, levels of a dopamine metabolite significantly increased in the spinal fluid.

The therapy resulted in clinical improvement of symptoms. Oculogyric crises, abnormal upward movements of the eyeballs, often with involuntary movements of the head, neck and body, that can last for hours and are a hallmark of the disease, completely went away in 6 of 7 participants. In some of the children, improvement was seen as early as nine days after treatment. One participant continued to experience oculogyric crises, but they were less frequent and severe.

All of the children exhibited improvements in movement and motor function. Following the surgery, parents of a majority of participants reported their children were sleeping better and mood disturbances, including irritability, had improved. Progress was also observed in feeding behavior, the ability to sit independently, and in speaking. Two of the children were able to walk with support within 18 months after receiving the gene therapy.

The gene therapy was well tolerated by all participants and no adverse side effects were reported. At three to four weeks following surgery, all participants exhibited irritability, sleep problems, and involuntary movements, but those effects were temporary. One of the children died unexpectedly seven months after the surgery. The cause of death was unknown but assessed to be due to the underlying primary disease.

Jill Morris, Ph.D., program director, NIHs National Institute of Neurological Disorders and Stroke (NINDS). To arrange an interview, please contact nindspressteam@ninds.nih.gov

Pearson TS et al., Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons, Nature Communications, July 12, 2021. https://doi.org/10.1038/s41467-021-24524-8

This study was supported by NINDS (R01NS094292, NS073514-01).

The NINDS NINDS is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Read the original:
funded study finds gene therapy may restore missing enzyme in rare disease - National Institutes of Health

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week – The Motley Fool

What happened

Companies associated with gene-editing are near the end of their second poor week in a row on Wall Street. For the week, shares of CRISPR Therapeutics (NASDAQ:CRSP) were down by 12% as of Thursday's market close. Editas Medicine (NASDAQ:EDIT) was off by about 14% over those four days, and Beam Therapeutics (NASDAQ:BEAM) had lost 15%.

Those downward moves came on the heels of a huge June run-up after Intellia Therapeutics (NASDAQ:NTLA) -- another gene-editing company -- announced that its approach had successfully reversed a genetic disease in human patients. In a clinical trial first, researchers injected a CRISPR treatment into patients that effectively inactivated the body's production of a mutated (and eventually toxic) form of a protein by altering the patients' DNA. Intellia and its partner Regeneron will now navigate the standard regulatory review process. Intellia CEO John Leonard has said he hopes the therapy becomes available to patients "very, very soon." However, marketability could still be years away. Meanwhile, Wall Street's recent surge of excitement about CRISPR therapies has worn off.

BEAM data by YCharts

The drops are notable as investors initially saw this breakthrough result as a positive for all gene-editing stocks. CRISPR Therapeutics, Editas, and Intellia are all taking similar approaches to editing genes -- using the CRISPR-Cas9 enzyme, which functions like a scissors. Beam Therapeutics, on the other hand, uses base-editing, an approach that alters DNA more like a pencil and eraser. Nearly three weeks removed from Intellia's announcement, the market has clearly decided its breakthrough is much more company-specific.

Image source: Getty Images.

It appears gene-editing investors who don't hold Intellia will have to wait for their own companies' catalysts to see big gains. Of these three, CRISPR Therapeutics is the one whose lead candidate is furthest along in clinical trials. CRISPR and its partner, Vertex Pharmaceuticals, have dosed more than 40 patients in a trial studying CTX001 in patients with sickle cell and beta-thalassemia. All patients at least three months removed from the procedure have shown a consistent and positive response to CTX001. Every previously transfusion-dependent patient in the trial has become transfusion-free since receiving the one-time treatment.

CTX001 is currently in a phase 1/2 study, and CRISPR Therapeutics hasn't offered any estimates about when it anticipates that it could be commercially available. But it recently signed an agreement with a smaller startup, Capsida Biotherapeutics, to develop an in vivo therapy for two diseases -- amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia.

Editas has both in vivo and ex vivo (gene-editing done outside the body) candidates in early-stage clinical trials. Its in vivo candidate, EDIT-101, is a treatment for the most common form of childhood blindness. For this program, management has a meeting scheduled with the independent data monitoring committee this summer, and plans to share clinical data by the end of the year.

The company's also developing an ex vivo treatment for sickle cell disease that takes a slightly different approach than the one being used by other gene-editing companies. Editas is using the Cas12a enzyme instead of the more commonly used Cas9. The Cas12a approach has shown better editing efficiency in some studies and only requires one RNA molecule for editing as opposed to Cas9, which requires two.

For now, Beam Therapeutics is furthest back on the research and development path. Its programs are in preclinical stages. Its most advanced candidate also targets sickle cell disease and beta-thalassemia.

Investors' excitement about Beam has been less about its individual treatments and more about the gene-editing technology the company is using. Its base-editing approach could offer a more precise and predictable tool to modify DNA for treating diseases. The company hopes that will allow it to effectively leapfrog its rivals in the next few years. Management has predicted it will file with the FDA for an investigational new drug (IND) designation for its lead candidate later this year. Receiving that designation will give it the green light to test the treatment in humans trials. It also plans to move two more programs into the IND-enabling stage.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Read the original post:
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week - The Motley Fool

M6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage Disorders – Business Wire

ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics (M6PT or the Company), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that it will host a key opinion leader (KOL) webinar on LSDs on Wednesday, July 28, 2021 at 10:00 a.m. ET.

The webinar will feature a fireside chat with KOLs Gregory Enns, M.D., Lucile Salter Packard Childrens Hospital Stanford School of Medicine, and Mark S. Sands, Ph.D., Departments of Medicine and Genetics at Washington University School of Medicine, who will discuss the current treatment landscape and unmet medical needs in LSDs, including Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidoses, and mucolipidoses. LSDs are a family of approximately 50 rare, genetic, and life-threatening diseases characterized by a deficiency in a specific lysosomal enzyme.

The event will also feature an update from the M6PT management team on its recombinant enzyme and gene therapy S1S3 bicistronic technology platform for the treatment of LSDs. The Company plans to initiate its first clinical program in 2022.

Dr. Enns, Dr. Sands, and M6PT management will also take questions from the audience.

To register for the webinar, please click here.

Dr. Enns is a Professor of Pediatrics and Genetics at the Lucile Salter Packard Childrens Hospital Stanford School of Medicine. He completed his medical education at the University of Glasgow (1990) in Scotland and completed his residency at the Children's Hospital Los Angeles Pediatric Residency in California. He then went on to complete his fellowship at the UCSF Medical Center in California. He is board certified in Clinical Genetics and Genomics. Dr. Enns research interests include novel means of diagnosing and treating mitochondrial disorders, with an emphasis on antioxidant therapy, lysosomal disorders, and newborn screening by tandem mass spectrometry. His current pursuits include the analysis of glutathione and antioxidant status in patients who have mitochondrial disorders and the development of new techniques for diagnosing and treating these conditions.

Dr. Sands is a Professor in the Departments of Medicine and Genetics at Washington University School of Medicine in St. Louis. Dr. Sands received his Ph.D. in Molecular Pharmacology from the State University of New York at Stony Brook. He was a postdoctoral fellow at The Jackson Laboratory (Bar Harbor, ME) and at the University of Pennsylvania School of Veterinary Medicine before joining the faculty at Washington University School of Medicine. The goals of Dr. Sands laboratory are to better understand the underlying pathogenesis and developing effective therapies for inherited childhood diseases, specifically LSDs. A major focus of his group is to determine the safety and efficacy of adeno-associated viral gene transfer vectors for the treatment of both the central nervous system (CNS) and systemic manifestations of these diseases. In addition, his group has developed lentiviral-mediated hematopoietic stem cell-directed gene therapy approaches, as well as small molecule drugs, and more recently rational combinations of these approaches. The primary diseases that Dr. Sands studies are mucopolysaccharidosis type VII (MPS VII), Krabbe disease, and Infantile Neuronal Ceroid Lipofuscinosis.

About M6P Therapeutics

M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics proprietary S1S3 bicistronic platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of recombinant enzyme and gene therapies by harnessing the power of protein phosphorylation using its S1S3 bicistronic platform. M6P Therapeutics mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: http://www.m6ptherapeutics.com.

See the article here:
M6P Therapeutics to Host Key Opinion Leader Webinar on Lysosomal Storage Disorders - Business Wire

Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Team – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced today the appointment of Howard Liang, Ph.D., as President and Chief Financial Officer. The company also expanded its executive bench with newly promoted talent and hires: Madhusudan Peshwa, Ph.D., as Chief Technology Officer for Cell Therapy; Bill Querbes, Ph.D., as Senior Vice President, Therapeutic Discovery & Translational Sciences; Cecilia Cotta-Ramusino, Ph.D. as Senior Vice President, Platform Development; Vikram Ranade, Ph.D., as Senior Vice President, Corporate Development; David Pollard, Ph.D., as Head of Bioprocess, and Steve Garbacz as Head of Finance.

These additions represent the latest leadership expansion for the company, following the appointments of Elliott Sigal, M.D., Ph.D., and Mary Rozenman, Ph.D., to the Board of Directors in June, and the appointments of David Davidson, M.D., as Chief Medical and Development Officer, Hari Pujar, Ph.D., as Chief Operating Officer, and Lin Guey, Ph.D., as Senior Vice President of Rare Diseases Program Strategy and Operations in March. Tessera also announced the successful completion of $230 million Series B financing in January.

Outstanding people are the lifeblood of great companies and Im thrilled to welcome these accomplished individuals to the Tessera leadership team, said Dr. Geoffrey von Maltzahn, CEO and Co-Founder of Tessera and General Partner, Flagship Pioneering. Howards track record in both strategy and finance at BeiGene and in the capital markets will play a key role in guiding Tessera to new territory in Gene Writing. I am excited to be working with him, and our other new senior leaders, each of whom will be instrumental in expanding the limits of how we discover life-changing medicines.

Howard Liang, Ph.D., President and Chief Financial OfficerHoward Liang joined Tessera in 2021 as President and Chief Financial Officer. Dr. Liang brings nearly three decades of combined experience in management, financing, strategy, and research in the biotechnology and pharmaceutical industries and investment research on Wall Street. Prior to joining Tessera, he was Chief Financial Officer and Chief Strategy Officer at BeiGene for six years, where he was a member of the senior team that led the companys growth from a research organization with fewer than 200 employees to a fully integrated global biotechnology company with more than 6,000 employees on five continents. At BeiGene, he led the companys IPOs on NASDAQ and the Hong Kong Stock Exchange and its ongoing effort to list on the Shanghai Stock Exchange, raising more than $8 billion to date through equity and alternative financings, and overseeing the growth of the companys market capitalization from less than $300 million to more than $30 billion during his tenure. Prior to BeiGene, Dr. Liang spent 10 years at Leerink Partners, where he was Managing Director and Head of Biotechnology Equity Research. His prior investment research experience included positions at A.G. Edwards, JMP Securities, and Prudential Securities, covering biotechnology, and major and specialty pharmaceutical sectors. He started his career in R&D at Abbott Laboratories, where he was a Senior Scientist and member of an industry-leading structure-based drug discovery team. Dr. Liang is a member of the Hong Kong Stock Exchange Biotech Advisory Panel. He was named a member of the All-America Research Team by Institutional Investor magazine and Best of the Street by The Wall Street Journal. As a scientist, he authored 14 papers, including 6 in Nature, Science, and Proceedings of the National Academy of Sciences, and a review in the Journal of Molecular Biology. He received his Ph.D. in Biochemistry and Molecular Biology and M.B.A. from the University of Chicago and his B.S. in Chemistry from Peking University.

Tessera is developing a first-of-its-kind technology with the potential to cure diseases across multiple categories by writing in the code of life itself, said Dr. Howard Liang. I look forward to helping the company realize the full breadth of Gene Writings potential.

Madhusudan Peshwa, Ph.D., Chief Technology Officer for Cell TherapyDr. Peshwa joined Tessera in May 2021 and is responsible for developing the strategy and executing the operating plan encompassing the design, development, and manufacture of Tesseras proprietary mobile gene element engineered cell therapy product portfolio. Recently, in March 2020, Dr. Peshwa was inducted into the College of Fellows at the American Institute for Medical and Biological Engineering (AIMBE), in recognition of Lifetime contributions in Regenerative Medicine to the advancements in the field of cell & gene therapies.

Prior to joining Tessera, Dr. Peshwa was CTO at Mana Therapeutics, an immunotherapy company focused on the development of allogeneic, multi-tumor-antigen-targeted, non-engineered, T-cell immunotherapies with additional oversight of Quality Assurance and Quality Control functions. Previously, Dr. Peshwa was CTO and Global Head of R&D for the Cell and Gene Therapies business at GE Healthcare (GEHC), with responsibilities that include GEHCs CGT product and service portfolio to enable and accelerate the development of robust, scalable, industrialized manufacturing and delivery of cell and gene therapies. Prior to these roles, Dr. Peshwa held various executive positions at MaxCyte, Inc., NewNeural LLC, and Dendreon Corporation. At MaxCyte, as CSO and EVP, Cellular Therapies, Dr. Peshwa was responsible for leading the development and commercialization of ex vivo cell loading platform technology. Additionally, he also established MaxCytes proprietary therapeutic product portfolio with lead program being a non-viral mRNA engineered CAR Immunotherapy (CARMA) with one-day manufacturing process under company sponsored IND for treatment of solid cancers; and additional collaborative programs under CRADA Agreement with Investigators at NIAID and NHLBI, for ex vivo gene correction in autologous hematopoietic stem cells, as cell therapy for potential treatment of monogenic diseases. As Vice President of Process Sciences and Manufacturing, at Dendreon Corporation, Dr. Peshwa was responsible for leading the CMC and GMP manufacturing for Provenge (Sipuleucel-T), an autologous cellular immunotherapy product for treatment of prostate cancer, the first ever active cellular immunotherapy product approved by the US FDA.

In addition to his broad industry experience, Dr. Peshwa has served as Principal Investigator / Co-Investigator on multiple grant-funded research studies, is an inventor of six issued US patents in the field of cell therapy, and has served in various consultative, advisory, and board capacities to industry, government, not-for-profit, and financial organizations. Dr. Peshwa earned his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology in Kanpur, India.

Tesseras Gene Writing platform represents an opportunity to drive a fundamental change in our ability to treat disease, said Dr. Madhusudan Peshwa. I look forward to joining the executive team to help move Tesseras bold mission forward.

Bill Querbes, Ph.D., Senior Vice President, Therapeutic Discovery & Translational SciencesBill Querbes joined Tessera in April of 2021 as Senior Vice President of Therapeutic Discovery and Translational Sciences. He brings a strong background in genetic medicine and a passion for rare disease drug development with over 15 years of experience leading cross-functional teams from early discovery through clinical trials.

Before joining Tessera, Dr. Querbes held the position of Vice President and Fabry Program Lead at AVROBIO. Prior to this role, as Senior Director at Synlogic, he led clinical program teams in PKU and urea cycle disorders. Earlier in his career he spent 12 years at Alnylam Pharmaceuticals where he made important contributions to the maturation of both the siRNA delivery platforms and therapeutic pipeline. Dr. Querbes led the discovery and early clinical development of GIVLAARI (givosiran) for the treatment of acute hepatic porphyria, which was the first FDA approved RNAi therapeutic utilizing GalNAc conjugate technology.

He holds a B.S. in Biology from SUNY Geneseo and a Ph.D. from Brown University.

Cecilia Cotta-Ramusino, Ph.D., Senior Vice President, Platform DevelopmentCecilia Cotta-Ramusino joined Tessera in 2019 as the Head of Platform Development. She drives the discovery and optimization of novel Gene Writers, enabling their translation into gene therapy tools. Dr. Cotta-Ramusino has spent more than 20 years in academia and biotech, working in the areas of gene editing, cell engineering, and DNA damage. Dr. Cotta-Ramusino was the first employee at insitro where she was the Head of Functional Genomics. Prior to insitro, she was one of the first scientists hired at Editas, the first CRISPR-based therapeutic company, where she helped to define and shape the vision of the Editas platform. She spearheaded numerous academic collaborations devoted to platform optimization and led the development of a T cell gene therapy treatment aiming to treat an immunodeficiency disease. She conducted her postdoc in Steve Elledges lab at Harvard Medical School where she performed whole genome high-throughput screens in mammalian cells using siRNA/shRNA to identify novel components of the DNA damage response. Dr. Cotta-Ramusino obtained her Ph.D. in genetics at University of Milan, Italy and has been principal author and co-author on several publications in high impact factor journals, such as Science, Nature, Nature Communications and Molecular Cell. She has invented several foundational patents in all of the early-stage companies in which she has worked.

Vikram Ranade, Ph.D., Senior Vice President, Corporate DevelopmentDr. Ranade joined Tessera in 2020 as the Head of Corporate Development. In this role, he drives corporate strategy, business development, and investor relations for Tessera.

Dr. Ranade was previously at McKinsey & Company, where he was an Associate Partner in the healthcare practice. At McKinsey, he worked with large biopharma and early-stage biotech companies on strategy, M&A, and R&D topics. He led diligence efforts for more than $15B in completed deals and advised on clinical strategy for more than 20 programs. Dr, Ranade also co-led McKinseys Center for Asset Optimization, which focuses on clinical-stage asset development strategy. He holds a Ph.D. in Genetics and Development from Columbia University, where he studied transcriptional regulation of developmentally important genes at the molecular level. He has a B.S. in biochemistry from Brandeis University, where he was awarded highest honors for his research on DNA damage repair pathways.

David Pollard, Ph.D., Head of BioprocessDavid Pollard has over 25 years of bioprocess development for a range therapeutics including novel mAbs, peptides, anti infectives, biocatalysts and more recently cell and gene therapies. During his career at Merck & Co. Inc, Dr. Pollard led early and late stage CMC teams, providing contributions to multiple INDs & BLAs for Biologics & Vaccines. Dr. Pollard also led an innovation team that co-developed the state-of-the-art ambr250 high throughput bioreactor system and also pioneered lights out automated continuous mAb production. More recently Dr. Pollard pursued processing for personalized neoantigen T cell therapies and helped create corporate research for the technology provider Sartorius. Dr. Pollard will help Tessera drive digital workflows and high throughput automation to accelerate sustainable gene therapy process development.

Steve Garbacz, Head of FinanceSteve Garbacz joined Tessera in 2021 as the Head of Finance and is responsible for financial reporting, planning, taxes, and treasury. Garbacz has more than 25 years of experience in financial management for a range of companies, including Biogen, Epizyme, Spero, and Anika. He has a passion for building scalable financial organizations leveraging new technology, and drove successful IPOs at Epizyme and Spero. At Anika, Garbacz was a key leader in acquiring and integrating two private companies. Garbacz has a B.S. in Economics from George Mason University and an MBA in Finance from the Leonard Stern School of Business at New York University.

For more information about Tessera, including how Gene Writing works, partnership opportunities, and job openings, visit http://www.tesseratherapeutics.com.

About Tessera TherapeuticsTessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

Read more here:
Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Team - Business Wire

Your Healthy Family: New gene therapy providing hope for those with rare genetic disorders – KOAA.com Colorado Springs and Pueblo News

COLUMBUS, OHIO A novel method of gene therapy is helping children born with a rare genetic disorder called AADC deficiency that causes severe physical and developmental disabilities. The study, led by researchers at The Ohio State University Wexner Medical Center and The Ohio State University College of Medicine, offers new hope to those living with incurable genetic and neurodegenerative diseases.

Research findings are published online in the journal Nature Communications.

This study describes the findings from the targeted delivery of gene therapy to midbrain to treat a rare deadly neurodevelopmental disorder in children with a neurogenetic disease, aromatic L-amino acid decarboxylase (AADC) deficiency characterized by deficient synthesis of dopamine and serotonin.

Only about 135 children worldwide are known to be missing the enzyme that produces dopamine in the central nervous system, which fuels pathways in the brain responsible for motor function and emotions. Without this enzyme, children lack muscle control, and are usually unable to speak, feed themselves or even hold up their head. They also suffer from seizure-like episodes called oculogyric crises that can last for hours.

Remarkably, these episodes are the first symptom to disappear after gene therapy surgery, and they never return, said study co-author Dr. Krystof Bankiewicz, professor of neurological surgery at Ohio State College of Medicine who leads the Bankiewicz Lab. In the months that follow, many patients experience life-changing improvements. Not only do they begin laughing and have improved mood, but many are able to begin speaking and even walking. They are making up for the time they lost during their abnormal development.

The directed gene therapy in seven children ages 4 to 9 who were infused with the viral vector resulted in dramatic improvement of symptoms, motor function and quality of life. Six children were treated at UCSF Benioff Childrens Hospital in San Francisco and one at Ohio State Wexner Medical Center. This therapeutic modality promises to transform the treatment of AADC deficiency and other similar disorders of the brain in the future, Bankiewicz said.

During the gene therapy surgery, physicians infuse a benign virus programmed with specific DNA into precisely targeted areas of the brain. The infusion is delivered extremely slowly as surgeons monitor exactly how it spreads within the brain using real-time MRI imaging.

Really, what we're doing is introducing a different code to the cell, said Dr. James Brad Elder, director of neurosurgical oncology at Ohio State Wexner Medical Centers Neurological Institute. And we're watching the whole thing happen live. So we continuously repeat the MRI and we can see the infusion blossom within the desired nucleus.

Researchers believe this same method of gene therapy can be used to treat other genetic disorders as well as common neurodegenerative diseases, such as Parkinsons and Alzheimers disease. Clinical trials are underway to test this procedure in others living with debilitating and incurable neurological conditions.

The directed gene therapy, in these patients, resulted in dramatic improvement of symptoms, motor function and quality of life. This therapeutic modality promises to transform the treatment of AADC deficiency and other similar disorders of the brain in the future.

The findings described in this study are the culmination of decades of work by teams from multiple academic institutions, including University of California San Francisco, Washington University in St. Louis, Medical Neurogenetics Laboratory in Atlanta, St. Louis Childrens Hospital and Nationwide Childrens Hospital in Columbus, Ohio.

The research was supported by the National Institute of Neurological Disorders and Stroke and foundational grants, including the AADC Research Trust, the Pediatric Neurotransmitter Disease Association and funding from The Ohio State University.

This work provides a framework for the treatment of other human nervous system genetic diseases. Its our hope that this will be first of many ultra-rare and other neurologic disorders that will be treated with gene therapy in a similar manner, Bankiewicz said.

Read the original post:
Your Healthy Family: New gene therapy providing hope for those with rare genetic disorders - KOAA.com Colorado Springs and Pueblo News

Researchers partner with industry to create better gene therapy tools – The Hub at Johns Hopkins

ByGina Wadas

Viruses are experts at infiltrating the body, as the SARS-CoV-2 virus (and resulting COVID-19 pandemic) have amply demonstrated. But their efficiency in targeting specific and isolated cells also make them useful drug delivery vehicles, known as viral vectors.

Viral vectors are modified viruses that can act as couriers to transport therapeutic "packages" to specific diseased cells. These packages contain instructions with modified or designed DNA or RNA to correct or supplement a faulty or missing gene. For instance, the Johnson & Johnson COVID-19 vaccine uses viral vectors to transport modified genetic material from the SARS-CoV-2 virus to cells, generating an immune response.

Though viral vector-based gene therapies are among the most advanced treatments for many congenital and acquired diseases, producing them is complex and costly.

"One of the major challenges in viral vector gene therapy is how to improve the quality, purity, and cost of the manufactured viral vectors, so that we can use the smallest possible effective dose, reduce immune side effects, and lower the cost of treatments," said Hai-Quan Mao, associate director and core faculty member of the Institute for NanoBioTechnology. He is also a professor in the departments of Materials Science and Engineering and Biomedical Engineering and a core faculty member at the Translational Tissue Engineering Center.

Hai-Quan Mao

Associate director, Institute for NanoBioTechnology

To address this challenge, Mao and his team are teaming up with Nolan Sutherland, senior scientist at bluebird bio, a Cambridge, Massachusetts-based biotechnology company that develops gene therapies. The partnership started about two years ago when Yizong Hu, a biomedical engineering PhD student under the mentorship of Mao, was at an annual meeting for the American Society for Gene and Cell Therapy presenting his research on a new particle assembly technology. Sutherland heard the presentation and approached Hu to discuss the technology and its application to the production of lentiviral vectors, which are made from a family of viruses that infect people by reverse transcription of their RNA into DNA in their host cells' genome.

Sutherland thought that the Mao team's approach might help streamline transfection, a key step in producing viral vectors. During transfection, a polymer solution is combined with a mixture of DNA plasmids to form transfection particles, a cumbersome procedure involving complicated solution blending and strictly timed dosing.

Mao, Hu, and Yining Zhu, also a biomedical engineering PhD student, developed a more effective and shelf-stable formulation of DNA particles in a ready-to-dose form. They also discovered that size-controlled sub-micron particles are most effective in transfecting cells and producing viral vectors. This production method is based on the team's years of experience in controlling transfection vehicle characteristics to enhance performances and stability.

The team members validated their findings with Sutherland at bluebird bio using that company's bioreactor. They compared the new method with the industry standard, and the results showed improved vector production yield, shelf stability, handling stability, and quality control of the transfection process.

"With the drastic increase in demand for lentiviral vector-based cell therapy products ... this new technology will greatly improve the production quality, consistency, and yield of our therapeutic LVVs," Sutherland said.

The team reported its findings in Nano Letters and is scaling up production with an eye to transferring the technology to the marketplace.

"This work represents a great example how we can partner with corporate collaborators to accelerate the translation of discoveries on the bench to the industry. This type of collaboration with industry provides us opportunities to identify the technical gaps in the engineering solutions that we develop, and fine tune them to better address the real-world problems in a more targeted fashion," Mao said.

According to Sutherland, the partnership with Mao and his team has "allowed bluebird to pursue high risk/reward innovation in a space outside of its core expertise. The team has a keen eye for application to industry which has made the partnership incredibly productive."

Team members say that this new particle engineering technology will find a wide range of applications in the manufacture of a variety of viral vectors for gene and cell therapy applications.

Also contributing to the project are Jordan Green, professor in the Department of Biomedical Engineering and associate member at the INBT, and Sashank Reddy, assistant professor of plastic and reconstructive surgery at Johns Hopkins Medicine, medical director at Johns Hopkins Technology Ventures, and affiliate faculty member at the INBT.

More here:
Researchers partner with industry to create better gene therapy tools - The Hub at Johns Hopkins

Dissecting the shared genetic basis of migraine and mental disorders using novel statistical tools. – Physician’s Weekly

Migraine is three times more prevalent in people with bipolar disorder or depression. The relationship between schizophrenia and migraine is less certain although glutamatergic and serotonergic neurotransmission are implicated in both. A shared genetic basis to migraine and mental disorders has been suggested but previous studies have reported weak or non-significant genetic correlations and five shared risk loci. Using the largest samples to date and novel statistical tools, we aimed to determine the extent to which migraines polygenic architecture overlaps with bipolar disorder, depression, and schizophrenia beyond genetic correlation, and to identify shared genetic loci. Summary statistics from genome-wide association studies were acquired from large-scale consortia for migraine (n cases=59,674; n controls=316,078), bipolar disorder (n cases=20,352; n controls=31,358), depression (n cases=170,756; n controls=328,443) and schizophrenia (n cases=40,675, n controls=64,643). We applied the bivariate causal mixture model to estimate the number of disorder-influencing variants shared between migraine and each mental disorder, and the conditional/conjunctional false discovery rate method to identify shared loci. Loci were functionally characterised to provide biological insights. Univariate MiXeR analysis revealed that migraine was substantially less polygenic (2.8K disorder-influencing variants) compared to mental disorders (8.1K-12.3K disorder-influencing variants). Bivariate analysis estimated that 0.8K (0.3K), 2.1K (SD=0.1K) and 2.3K (SD=0.3K) variants were shared between bipolar disorder, depression and schizophrenia, respectively. There was also extensive overlap with intelligence (1.8K, SD=0.3K) and educational attainment (2.1K, SD=0.3K) but not height (1K, SD=0.1K). We next identified 14 loci jointly associated with migraine and depression and 36 loci jointly associated with migraine and schizophrenia, with evidence of consistent genetic effects in independent samples. No loci were associated with migraine and bipolar disorder. Functional annotation mapped 37 and 298 genes to migraine and each of depression and schizophrenia, respectively, including several novel putative migraine genes such as L3MBTL2, CACNB2, SLC9B1. Gene-set analysis identified several putative gene-sets enriched with mapped genes including transmembrane transport in migraine and schizophrenia. Most migraine-influencing variants were predicted to influence depression and schizophrenia, although a minority of mental disorder-influencing variants were shared with migraine due to the difference in polygenicity. Similar overlap with other brain-related phenotypes suggests this represents a pool of pleiotropic variants which influence vulnerability to diverse brain-related disorders and traits. We also identified specific loci shared between migraine and each of depression and schizophrenia, implicating shared molecular mechanisms and highlighting candidate migraine genes for experimental validation. The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.

More:
Dissecting the shared genetic basis of migraine and mental disorders using novel statistical tools. - Physician's Weekly

Getting to the heart of genetic cardiovascular diseases | Penn Today – Penn Today

When she isnt pursuing her favorite heart-pumping activities of running, swimming, or cycling, Sharlene M. Day, a presidential associate professor of cardiovascular medicine and director of Translational Research for the Penn Cardiovascular Institute, is focused on the heart in another way; trying to unlock and treat the mysteries of genetic heart disease.

As part of her research at the Day Lab, Day integrates translational and clinical science to understand the full spectrum of genetic heart disease evolution and progression, from gene mutations in heart muscle cells to ways of predicting negative outcomes in patients. Clinically, she sees patients with hypertrophic cardiomyopathy, a condition where the heart muscle becomes thick making it harder for blood to leave the heart, and other genetic heart conditions at the Penn Center for Inherited Cardiac Disease, such as inherited arrhythmias, high blood cholesterol, Marfan syndrome and familial amyloidosis. Her research program primarily focuses on these same conditions.

A physician scientist, Day completed her residency, followed by a cardiology fellowship, and a postdoctoral research fellowship at the University of Michigan before joining the faculty there, and spent 24 years there before coming to Penn. Day was recruited to Penn Medicine to lead initiatives in translational research within the Cardiovascular Institute and to grow the clinical and academic mission in the Penn Center for Inherited Cardiovascular Disease.

Very early on in my training, I became fascinated with the interplay between genetics and cardiac physiology that manifest in very unique observable cardiac traits and complicated disease trajectories including both heart failure and arrhythmias, also known as irregular heartbeats, says Day.

This story is by Sophie Kluthe. Read more at Penn Medicine News.

Read this article:
Getting to the heart of genetic cardiovascular diseases | Penn Today - Penn Today

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults…

SAN RAFAEL, Calif., July 19, 2021 /PRNewswire/ --BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. The pivotal study demonstrated superiority to Factor VIII prophylaxis in key clinical efficacy endpoints. With 134 participants, this is the largest global Phase 3 study to date for gene therapy in hemophilia. All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Top-line one-year results from this study were previously communicated in January 2021.

New data presented at ISTH include more details on annualized bleeding rate (ABR) in all study participants and annualized Factor VIII utilization rate, in terms of international units per kilogram per year (IU/kg/year) of replacement Factor VIII. Over 90 percent (N=134) of all participants in the GENEr8-1 study had an annualized bleed rate (ABR) of zero or a lower bleed rate than baseline after week 4 after treatment with valoctocogene roxaparvovec.

New data presented at ISTH also include information on Factor VIII utilization after treatment with valoctocogene roxaparvovec. Mean annualized Factor VIII utilization rate, among a pre-specified group of prior participants in a non-interventional baseline observational study (rollover population; N=112) decreased from baseline on Factor VIII prophylaxis by 99% from 3961.2 (median 3754.4) to 56.9 (median 0) IU/kg/year after week 4 after treatment with valoctocogene roxaparvovec (p-value <0.001).

As previously shared in January 2021, data from the pre-specifiedrollover population(N=112)in the GENEr8-1 study with a mean follow-up of 71.6 weeks demonstrated that in the pre-specified primary analysis for ABR, calculated through each subject's last assessment, a single dose of valoctocogene roxaparvovec significantly reduced mean ABR by 84% from a prospectively collected 4.8 (median 2.8) at baseline to 0.8 (median 0.0) bleeding episodes per year (p-value <0.001).

In addition, the mean annualized Factor VIII infusion rate was reduced by 99% from 135.9 (median 128.6) to 2.0 (median 0.0) infusions per year (p-value <0.001).

Table 1: Mean/Median Annualized Bleeding Rate (ABR) and FVIII Infusion Rate in Phase 3 GENEr8-1 Study Rollover Population (N=112) after Week 4 Through Week 52 at November 2020 Cut Off

Phase 3

Rollover Population*

On Factor VIII prophylaxis, before valoctocogene roxaparvovec infusion

N=112

Phase 3

Rollover Population*

After valoctocogene roxaparvovec infusion

N=112

Mean (SD)

Median (IQR)

Mean (SD)

Median (IQR)

Annualized Bleeding Rate (bleeding episodes per year)

4.8 (6.5)

2.8 (0.0, 7.6)

0.8 (3.0)

0.0 (0.0, 0.0)

Annualized FVIIIUtilizationRate(IU per kgper year)

3961.2 (1751.5)

3754.4(2799.5, 4706.8)

56.9 (194.6)

0.0 (0.0,22.1)

Annualized FVIII Infusion Rate (infusions per year)

135.9 (52.0)

128.6 (104.1, 159.9)

2.0 (6.4)

0.0 (0.0, 0.9)

*See study description for patient population information.

Study participants also experienced a clinically meaningful increase in endogenous Factor VIII expression. At the end of the first year post-infusion with valoctocogene roxaparvovec, participants in the modified intent-to-treat (mITT) population (N=132) had a significant increase in mean endogenous Factor VIII expression level from an imputed baseline of 1 IU/dL to 42.9 IU/dL (median 23.9) (p-value <0.001) as measured by the chromogenic substrate (CS) assay, supporting the marked clinical benefits observed with abrogation of bleeding episodes and Factor VIII utilization and infusion rates. In a subset of the mITT population that had been dosed at least two years prior to the data cut date (N=17), Factor VIII expression declined from a mean of 42.2(median 23.9) IU/dL at the end of year one to 24.4 (median 14.7) IU/dL at the end of year two with continued hemostatic efficacy.

Table 2: Factor VIII Activity Levels in 12-Month Intervals

Median Factor VIII Activity, IU/dL

Phase 3 mITT Population*

(N=132)

Mean (SD)

Median

Phase 3 mITT Subset Population**

(N=17)

Mean (SD)

Median

Week 52

42.9 (45.5)

23.9 (11.9, 62.3)

42.2 (50.9)

23.9 (11.2, 55.0

Week 104

N/A

24.4 (29.2)

14.7 (6.4, 28.6)

*mITT= modified intent-to-treatpopulation, whichexcludes 2 HIV- positive subjects dosed 2 or more years prior to November 2020 data cut.

**Includes only HIV-negative subjects dosed 2 or more years prior to Nov 2020 data cut date. One participant was lost to follow-up at 66.1 weeks and was henceforth imputed to have a Factor VIII activity of 0 IU/dL through 104 weeks.

"The demonstrated bleed control at 52 weeks and beyond in this pivotal study supports our thesis that gene therapy can play an important role in the treatment of severe hemophilia A and potentially creates the possibility for a new treatment paradigm," said Margareth C. Ozelo, MD, PhD, Director, INCT do SangueHemocentroUNICAMP,University of Campinas and Lead Principal Investigator of the GENEr8-1 Study. "It is encouraging to see meaningful endogenous Factor VIII expression and decreases in bleeding and Factor VIII infusions for people in this study. These pivotal results contribute to the growing body of data to increase understanding of the safety and efficacy of gene therapy treatment over time."

"From the start of our valoctocogene roxaparvovec program, our goal remains to advance treatment options for people with severe hemophilia A in light of the unmet need in bleed control. Current prophylactic therapies for hemophilia A cannot maintain Factor VIII levels for sustained periods, leading to the need for frequent, regular infusions or injections while still having a risk of ongoing, unpredictable bleeds and unavoidable, irreversible joint damage even with standard of care treatment," said Hank Fuchs, M.D., President of Worldwide Research and Development at BioMarin. "These data build upon the foundation for a potential transformative treatment option that addresses the root cause of severe hemophilia A. Later at ISTH, we look forward to sharing five years of clinical data from the ongoing Phase 1/2 study with the longest duration of clinical experience, which complements this pivotal Phase 3 study, the largest study of a gene therapy in hemophilia A."

Valoctocogene Roxaparvovec Safety

Overall, in the Phase 3 study, valoctocogene roxaparvovec has been welltolerated by the 134participants who received a single 6e13 vg/kg dose. No participants withdrew due to adverse events. No participants developed inhibitors to Factor VIII, or experienced thromboembolic events. One participant was lost to follow-up. Infusion reactions were defined as any AEs occurring within 48 hours post-infusion. The most common infusion reactions were nausea (14.2%), fatigue (7.5%), and headache (6.0%). Systemic hypersensitivity during or following infusion was mitigated by slowing or pausing infusion and treating with supportive medications, as indicated. All four (3.0%) participants with an interruption due to infusion-related symptoms were able to complete their infusion. Twenty-two (16.4%) participants experienced a total of 43 serious adverse events (SAEs), and all SAEs resolved.

Common, steroid-related side effects can occur with temporary use of corticosteroid (or alternative immunosuppressants) to manage ALT elevation. ALT elevation was the most common AE. Overall, 79% of participants received corticosteroids per protocol as treatment for ALT elevation. The average duration of corticosteroid treatment was 33 weeks. Overall, 72% of participants who used any corticosteroidsreported AEs attributed to their use, most commonly acne, insomnia, cushingoid changes, and weight increased. Three participants reported SAEs attributed to corticosteroids. Other immunosuppressants were used by 29% of participants for ALT elevation due to contraindication, side effects, or poor or no response to corticosteroid treatment. No Grade 4 ALT elevations occurred, and no participants met Hy's law criteria for drug-induced liver injury.

GENEr8-1 Study Description

The global Phase 3 GENEr8-1 study evaluates superiority of valoctocogene roxaparvovec at the 6e13 vg/kg dose compared to FVIII prophylactic therapy. All study participants had severe hemophilia A at baseline, defined as less than or equal to 1 IU/dL of Factor VIII activity. The study included 134 total participants, all of whom had a minimum of 12 months of follow-up at the time of the data cut. The first 22 participants were directly enrolled into the Phase 3 study, 17 of whom were HIV-negative and dosed at least 2 years prior to the data cut date (referred to as the subset). The remaining 112 participants (rollover population) completed at least six months in a separate non-interventional study to prospectively assess bleeding episodes, Factor VIII use, and health-related quality of life while receiving Factor VIII prophylaxis prior to rolling over to receive a single infusion of valoctocogene roxaparvovec in the GENEr8-1 study.

Regulatory Status

The European Medicines Agency (EMA) validated BioMarin's resubmission of a Marketing Authorization Application (MAA) on July 15, 2021. In May 2021, the EMA granted the Company's request for accelerated assessment. Accelerated assessment potentially reduces the time frame for the EMA Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) to review a MAA for an Advanced Therapy Medicinal Product (ATMP), although an application initially designated for accelerated assessment can revert to the standard procedure during the review for a variety of reasons.The decision to grant accelerated assessment has no impact on the eventual CHMP and CAT opinion on whether a marketing authorization should be granted. A CHMP and CAT opinion is anticipated in the first half of 2022.

The MAA submission includes safety and efficacy data from the 134 subjects enrolled in the Phase 3 GENEr8-1 study, all of whom have been followed for at least one year after treatment with valoctocogene roxaparvovec, as well as four and three years of follow-up from the 6e13 vg/kg and 4e13 vg/kg dose cohorts, respectively, in the ongoing Phase 1/2 dose escalation study.

In the United States, BioMarin intends to submit two-year follow-up safety and efficacy data on all study participants from the Phase 3 GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, as previously requested by the Food and Drug Administration (FDA). BioMarin is targeting a Biologics License Application (BLA) resubmission in the second quarter of 2022, assuming favorable study results, followed by an expected six-month review by the FDA.

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec inMarch 2021. RMAT is an expedited program intended to facilitate development and review of regenerative medicine therapies, such as valoctocogene roxaparvovec, that are intended to address an unmet medical need in patients with serious conditions. The RMAT designation is complementary to Breakthrough Therapy Designation, which the Company received in 2017.

In addition to the RMAT Designation and Breakthrough Therapy Designation, BioMarin's valoctocogene roxaparvovec also has received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A.The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

Robust Clinical Program

BioMarin has multiple clinical studies underway in its comprehensive gene therapy program for the treatment of hemophilia A. In addition to the global Phase 3 study GENEr8-1 and the ongoing Phase 1/2 dose escalation study, the Company is actively enrolling participants in a Phase 3b, single arm, open-label study to evaluate the efficacy and safety of valoctocogene roxaparvovec at a dose of 6e13 vg/kg with prophylactic corticosteroids in people with hemophilia A. The Company is also running a Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with hemophilia A with pre-existing AAV5 antibodies, as well as another Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with hemophilia A with active or prior FVIII inhibitors.

About Hemophilia A

People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries. Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints. Individuals with the most severe form of hemophilia A make up approximately 45 to 50 percent of the hemophilia A population. People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed. The standard of care for adults with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year. Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life.

Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A.

About ISTH

Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The ISTH is an international professional membership organization with more than 7,700 clinicians, researchers and educators working together to improve the lives of patients in more than 110 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees and World Thrombosis Day on 13 October.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visitwww.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statements

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about (i) the development of BioMarin's valoctocogene roxaparvovec program generally, (ii) the anticipated timing of a CHMP and CAT opinion in the first half of 2022, (iii) BioMarin's intention to submit to the U.S. Food and Drug Administration (FDA) two-year follow-up safety and efficacy data on all study participants from the GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, (iv) BioMarin targeting resubmission of a Biologics License Application in the second quarter of 2022 assuming favorable study results, followed by an expected six-month review procedure by the FDA, (v) the anticipated Phase 1/2 study to be presented later at ISTH and (vi) the timing of the regulatory activities in the U.S andEurope, including validation and timing of potential approvals and the expected review procedures. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the above data and additional data from the continuation of these trials; any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the EMA and other regulatory authorities; the content and timing of decisionsby local and central ethics committees regarding the clinical trials; our ability to successfully manufacture valoctocogene roxaparvovec for the clinical trials and commercially, if approved; and those other risks detailed from time to time under the caption "Risk Factors" and elsewhere in BioMarin's Securities and Exchange Commission (SEC) filings, including BioMarin's Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2021, and future filings and reports by BioMarin... BioMarin undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.

Contacts:

Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

SOURCE BioMarin Pharmaceutical Inc.

Home

See more here:
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults...

2nd International Conference and Exhibition on Nanoscience and Nanotechnology November 13-15, 2021 – GlobalAtlanta

2nd International Conference and Exhibition on Nanoscience and Nanotechnology November 13-15, 2021

Register Online

To promote current research outcomes within the research communities to enhance their current knowledge in the field of Nanoscience and Nanotechnology and to discover new trends for future applications which are safer, cheaper and easier, OLC International is organizing the 2nd International Conference and Exhibition on Nanoscience and Nanotechnology which will be held during November 13-15, 2021 in Naples, Italy. The theme of the conference is Premodern and Modern Era Discoveries and Milestones in the Field of Nanotechnology.

This three-day event provides a platform for worldwide professionals to share their research outcomes and take part in intensive discussions on different aspects concerning this field. It will include several informative plenary talks, keynote lectures, panel discussions, workshops, poster and oral presentations, and other social events aimed at fostering partnerships between academic and business communities.

This conference will provide an opportunity to young researchers, celebrated scientists, policymakers, members of associations, and academic professionals to present their ideas to a large audience and to make new and lasting connections that will further career and business goals.

They look forward to welcoming you to this conference in Naples, Italy 2021.

Register Online

Link:
2nd International Conference and Exhibition on Nanoscience and Nanotechnology November 13-15, 2021 - GlobalAtlanta

With the HUMANS project, a message that space is for everyone – MIT News

When the Voyager 1 and Voyager 2 spacecraft launched in 1977, they each carried a Golden Record, a special project spearheaded by astrophysicist Carl Sagan, in addition to the scientific instruments necessary for their mission to explore the outer reaches of our solar system. Part time capsule, part symbolic ambassador of goodwill, the Golden Record comprises sounds, images, music, and greetings in 59 languages, providing a snapshot of life on Earth for the edification of any intelligent extraterrestrial beings the spacecraft might encounter.

Today, while Voyager 1 and 2 hurtle on through interstellar space more than 14 billion and 12 billion miles away, respectively, the Golden Record and the iconic etching on its cover has inspired a new student-run initiative, the Humanity United with MIT Art and Nanotechnology in Space (HUMANS) project, which aims to send a message that hits a little closer to home: that space is for everyone.

We want to invite the world to submit a message to our project website either text or audio, or both! sharing what space means to them and to humanity in their native languages, says project co-founder Maya Nasr, a graduate student in the Department of Aeronautics and Astronautics. Our goal is to use art and nanotechnology to create a symbol of unity that promotes global representation in space and brings awareness to the need for expanded access to the space sector worldwide.

Nasr and her fellow HUMANS project co-founder Lihui Lydia Zhang '21, a graduate of MIT's Technology Policy Program, are collecting submissions this summer into the fall semester via a submission portal on their website, humans.mit.edu. Taking inspiration from One.MIT, a project to etch more than 270,000 names from the MIT community on a 6-inch wafer, they have partnered with MIT.nano to etch both text and audio waveforms onto a 6-inch disk.

Finally, in collaboration with the Space Exploration Initiative (SEI) at the MIT Media Lab, this new record of our voices will travel to the International Space Station (ISS) on a future mission.

For both Nasr and Zhang, the philosophy space for all is personal. The two bonded over their shared experience as international students whose own passion for space brought them to MIT: Nasr grew up in Lebanon, while Zhang grew up in China. In their journeys in the space sector, they have both faced constant challenges and struggles that limited them from fully contributing their learning and passion.

These challenges generated a shared frustration, but more importantly, a vision that space should be more accessible and representative for more people around the world. As classmates in 16.891 (Space Policy Seminar) with Professor Dava Newman, they came across an open call for proposals for developing suborbital and ISS payloads from the SEI. Nasr and Zhang put their heads together to create their proposal for the HUMANS project.

The International Space Station is one of the few avenues that represents international cooperation in space, but there are still so many countries around the world that aren't included in that representation, says Zhang. The HUMANS project won't solve this problem, but we hope it will be a small step forward to help us advocate for expanding global access to space.

In addition to Nasr and Zhang, HUMANS project collaborators include faculty advisor Jeffrey Hoffman, professor of the practice in aeronautics and astronautics; advisor Ariel Ekblaw, director of SEI; website developer and rising senior Claire Cheng; Xin Lu and Sean Auffinger from SEI; Professor Craig Carter from the Department of Materials Science and Engineering (DMSE); and Georgios Varnavides, a graduate student in DMSE.

To participate in the HUMANS project, visit humans.mit.edu to submit a text and/or audio message. Messages must follow project guidelines to be included on the final disk that will be sent into space.

Link:
With the HUMANS project, a message that space is for everyone - MIT News

Nanotechnology in Drug Delivery Market to Witness Robust Expansion by 2027 |Alkermes, Access Pharmaceuticals, Camurus, Celgene, Capsulution Pharma 26…

There has been major expansion in the transformation of nano-based cancer therapies and diagnostics and different new technologies are in the pipeline. Nanomedicine and nano delivery systems are being utilized as diagnostic tools or in delivering therapeutic agents to specific targeted sites in a controlled manner wherein materials are used in the nanoscale range

Nanotechnology in Drug Delivery Market from the perspective of all its current trends that are influencing it is important to understand in order to obtain the most rounded solution for business strategies in it. These trends are geographical, socioeconomic, economic, consumer, political, cultural, and their overall effect on client or consumer preferences will have a major data in how this market will form itself in the following years to come. Dynamics and the way they impact the global Nanotechnology in Drug Delivery market have been studied in absolute precise details in the report. The ultimate goal for the dissemination of this information is to create a detailed descriptive analysis of how these trends could potentially affect the future of the global Nanotechnology in Drug Delivery market within the reports forecast period..

Top Key Players Profiled in this report are Alkermes, Access Pharmaceuticals, Camurus, Celgene, Capsulution Pharma, Aquanova.

Get Sample Copy of this report with latest Industry Trend and COVID-19 Impact @:

https://www.a2zmarketresearch.com/sample?reportId=412269

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Nanotechnology in Drug Delivery market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

This report studies the global Nanotechnology in Drug Delivery market, analyzes and researches the development status and forecast in North America, Asia Pacific, Europe, the Middle East & Africa and Latin America. Various key players are discussed in details and a well-informed idea of their popularity and strategies is mentioned.

The study segments the market by geography into: North America, Europe, Asia Pacific, and Rest of the World. It provides in-depth forecasts of revenue of the market as a whole as well as each and every application segment. The competitive landscape is mapped depending on product and technology. This study also offers an overview of pricing trends and ancillary factors that will be influencing pricing in the global Nanotechnology in Drug Delivery market. The market study, estimation, and market sizing have been done utilizing a combination of top-down and bottom-up approaches.

Global Nanotechnology in Drug Delivery Market Segmentation:

Market Segmentation: By Type

Targeted DeliveryDrug Package

Market Segmentation: By Application

CancerTumorOther

Get Special Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=412269

The global Nanotechnology in Drug Delivery market is also presented to the readers as a holistic snapshot of the competitive landscape within the given forecast period. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of where areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the global market.

Global Nanotechnology in Drug Delivery Market research report offers:

Table of Contents

Global Nanotechnology in Drug Delivery Market Research Report 2021 2027

Chapter 1 Nanotechnology in Drug Delivery Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Nanotechnology in Drug Delivery Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=412269

If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Go here to see the original:
Nanotechnology in Drug Delivery Market to Witness Robust Expansion by 2027 |Alkermes, Access Pharmaceuticals, Camurus, Celgene, Capsulution Pharma 26...